Colorectal, breast and lung cancer patients commencing adjuvant systemic treatment Cancer Malignant neoplasm of breast, Malignant neoplasm of bronchus and lung
Conditions
Interventions
180 colorectal, breast and lung cancer patients commencing adjuvant systemic treatment (chemotherapy+/-targeted therapies) will be enrolled into a prospective, multi-centre two-arm parallel-group RCT
Sponsors
University of Surrey
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with breast, colorectal and lung cancer who have just had surgery for their primary cancer and are about to commence adjuvant chemotherapy as part of their treatment will be approached in oncology clinics to see if they would like to participate: 1. Adults (age >18 years) commencing adjuvant cytotoxic chemotherapy at participating site for the minimum planned duration of 12 weeks 2. Breast, colorectal or lung cancer diagnosis 3. Primary disease completely excised R0 with no evidence of macroscopic residual or metastatic disease 4. Smartphone access that conforms to the following specifications: 4.1. Apple devices running iOS 9.2 (or later) or devices running Android 4.4 (or later) 4.2. Screen size of at least 4.7 inches (equivalent to an iPhone 6) 5. Able to read and write in English (Information will be provided in the Welsh language if requested for the Welsh site) 6. Able to provide informed consent
Exclusion criteria
Exclusion criteria: 1. Systemic anti-cancer treatment to palliate incurable cancer for this malignancy 2. No longer undergoing systemic therapy 3. No smartphone access 4. Unable to read or write in English 5. Significant cognitive impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Health-related QoL measured using FACT-G (PWB) at baseline, (then 6, 12, 18) and 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.1. Patient compliance with patient-reported outcome (PRO) data collection measured using FACT-G (PWB), EQ5D, QLQ-C30 at baseline, then 6, 12, 18 and 24 weeks 1.2. Patient self-management of symptoms measured using EQ-5D-5L and EORTC QLQ-C30 at baseline, then 6, 12, 18 and 24 weeks 2. Process of care and emergency healthcare utilisation (medication adherence, A&E/GP visits/admissions, acute oncology hotline utilisation, concomitant medications) measured by asking participants (at their clinic visits) and reviewing their medical records at baseline, then 6, 12, 18 and 24 weeks | — |
Countries
England, United Kingdom, Wales
Contacts
Public ContactAgnieszka Michael
Outcome results
None listed